CN Patent

CN113348163B — 方法和化合物

Assigned to Radius Pharmaceuticals Inc · Expires 2024-10-08 · 2y expired

What this patent protects

描述了用于制备化合物1的有用制备方法和中间体，所述化合物是选择性雌激素受体α(ERα)调节剂/降解剂(SERM/SERD)，其具有治疗ER+癌症包括乳腺癌的效用。

USPTO Abstract

描述了用于制备化合物1的有用制备方法和中间体，所述化合物是选择性雌激素受体α(ERα)调节剂/降解剂(SERM/SERD)，其具有治疗ER+癌症包括乳腺癌的效用。

Drugs covered by this patent

elacestrant-hydrochloride (ELACESTRANT HYDROCHLORIDE)

Patent Metadata

Patent number: CN113348163B
Jurisdiction: CN
Classification: —
Expires: 2024-10-08
Drug substance claim: No
Drug product claim: No
Assignee: Radius Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.